GVS-18-B35
Version 1.761db74e · 2026-09-13
| CAS No. | Not available |
| Chemical Name | GVS-18-B35 |
| Synonyms | GVS18B35， GVS 18 B35， |
| SMILES | CCCCC/C=C\CCCO[Si](CCCCCCN(C)C)(OCCC/C=C\CCCCC)OCCC/C=C\CCCCC |
| Formula | C38H75O3NSi |
| M.Wt | 622.11 |
| Purity | >98% |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Not available |
GVS-18-B35 is a leading silicon ether-based ionizable lipid that demonstrates exceptional performance in mRNA delivery. It features a biodegradable silyl ether linkage, which undergoes rapid, non-enzymatic hydrolysis, enabling near-complete clearance from the liver within 24 hours in both mice and non-human primates (NHPs). This degradation mechanism is independent of variable enzymatic activity, ensuring consistent pharmacokinetics across species. In vivo, GVS-18-B35 lipid nanoparticles (LNPs) achieve superior liver-specific protein expression with minimal off-target accumulation in the spleen, resulting in a high liver-to-spleen signal ratio and reduced immune stimulation. The LNPs exhibit excellent stability under frozen storage (-80°C) and maintain critical quality attributes, including particle size, polydispersity, and encapsulation efficiency, through multiple freeze-thaw cycles. With an optimal pKa (~6.3) and enhanced endosomal escape capability, GVS-18-B35 represents a robust and versatile platform for mRNA therapeutics, particularly suited for applications requiring frequent dosing due to its unique combination of high potency and rapid clearance profile.
Specifications shown are product-page values, not batch test results.
Read Instructions for Use →